The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines

Cancer Letters
Sung-Han HsiaoChung-Pu Wu

Abstract

The overexpression of ABCB1 in cancer cells is a major factor contributing to the development of multidrug resistance (MDR) and treatment failure in cancer patients. Therefore, re-sensitization of MDR cancer cells to anticancer drugs remains an important aspect in chemotherapy. The progress in developing clinically applicable synthetic inhibitors of ABCB1 has been slow, mostly due to complications associated with intrinsic toxicities and unforeseen drug-drug interactions. Here, we explored the drug-repositioning approach for cancer therapy by targeting ABCB1-mediated MDR in human cancer cells. We found that DPI-201106, a positive inotropic agent, selectively inhibits the drug efflux function of ABCB1, and in doing so, re-sensitizes ABCB1-overexpressing MDR cancer cells to conventional anticancer drugs. Furthermore, the ATPase activity of ABCB1 and docking analysis of DPI-201106 in the drug-binding pocket of ABCB1 were determined to confirm the interaction between DPI-201106 and ABCB1 protein. In summary, we revealed an additional action and a potential clinical application of DPI-201106 to reverse ABCB1-mediated MDR in human cancer cells, which may be beneficial for cancer patients who have developed multidrug resistance and no...Continue Reading

References

Nov 1, 1990·International Journal of Cardiology·M E DavisR K Walesby
Nov 1, 1985·Journal of Cardiovascular Pharmacology·R P Hof, A Hof
Dec 1, 1987·The American Journal of Cardiology·J B KostisL A Casazza
Oct 1, 1986·British Journal of Pharmacology·G Scholtysik, F M Williams
Nov 1, 1994·Clinical and Experimental Pharmacology & Physiology·S DoggrellL Brown
May 11, 1994·Biochimica Et Biophysica Acta·Z HollóB Sarkadi
Feb 15, 1994·European Journal of Pharmacology·D S KrafteA M Ezrin
May 20, 1999·Annual Review of Pharmacology and Toxicology·S V AmbudkarM M Gottesman
Aug 18, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·M MevissenG Scholtysik
Feb 22, 2002·Cardiovascular Drugs and Therapy·M Flesch, E Erdmann
Mar 21, 2002·Nature Reviews. Cancer·Michael M GottesmanSusan E Bates
Apr 5, 2003·Toxicology Letters·Adrienn BodóBalázs Sarkadi
Oct 25, 2003·Oncogene·Suresh V AmbudkarMichael M Gottesman
Feb 20, 2004·Cancer Research·Robert W RobeySusan E Bates
Apr 23, 2005·Toxicology and Applied Pharmacology·Elaine M LeslieSusan P C Cole
Nov 23, 2005·Bioinformatics·Konstantin ArnoldTorsten Schwede
Feb 6, 2008·Expert Opinion on Drug Metabolism & Toxicology·Suneet ShuklaSuresh V Ambudkar
Apr 30, 2009·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Alma HamidovicJill Kolesar
Dec 2, 2009·Methods in Molecular Biology·Jean-Pierre Gillet, Michael M Gottesman
Dec 8, 2010·Bioinformatics·Pascal BenkertTorsten Schwede
Jul 21, 2011·Molecular Pharmaceutics·Chung-Pu WuYu-Shan Wu
Oct 5, 2011·Essays in Biochemistry·Akina TamakiSusan E Bates
Oct 4, 2012·Bioorganic & Medicinal Chemistry Letters·María L CuestasVerónica L Mathet
Oct 19, 2013·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Yasuhiro TajimaThomas Efferth
May 2, 2014·Nucleic Acids Research·Marco BiasiniTorsten Schwede
Jan 11, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Raquel C MaiaVivian M Rumjanek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.